Amyotrophic lateral sclerosis (ALS)
is a fatal neurodegenerative
disease without any effective treatment. Protein TDP-43 is a pathological
hallmark of ALS in both sporadic and familiar patients. Post-translational
modifications of TDP-43 promote its aggregation in the cytoplasm.
Tau-Tubulin kinase (TTBK1) phosphorylates TDP-43 in cellular and animal
models; thus, TTBK1 inhibitors emerge as a promising therapeutic strategy
for ALS. The design, synthesis, biological evaluation, kinase–ligand
complex structure determination, and molecular modeling studies confirmed
novel pyrrolopyrimidine derivatives as valuable inhibitors for further
development. Moreover, compound 29 revealed good brain
penetration in vivo and was able to reduce TDP-43
phosphorylation not only in cell cultures but also in the spinal cord
of transgenic TDP-43 mice. A shift to M2 anti-inflammatory microglia
was also demonstrated in vivo. Both these activities
led to motor neuron preservation in mice, proposing pyrrolopyrimidine 29 as a valuable lead compound for future ALS therapy.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.